Abstract
In daily practice, chemical substances called “direct oral anticoagulants” or DOACs are more convenient to administer when set beside vitamin K antagonists (VKA) due to improved pharmacologic properties, fewer drug interactions and rapid onset of action. The objective of this review was to assess whether DOACs are the alternative for VKA in subjects with mild-to-moderate chronic kidney disease (CKD). An analysis of current DOAC trials and studies was performed focusing on subjects with CKD. This review concludes that although DOACS are not recommended in the course of advanced chronic kidney disease (CrCl<30mL/min) or during dialysis, DOACS are a reasonable choice for individuals with mild to moderate CKD.
Keywords: Anticoagulants, chronic kidney disease, direct oral anticoagulants, vitamin K antagonists, pharmacologic properties, dialysis.
Current Pharmaceutical Design
Title:Safety of New Oral Anticoagulants for Patients with Chronic Kidney Disease
Volume: 24 Issue: 38
Author(s): Krasiński Zbigniew*, Stępak Hubert, Jawień Andrzej and Stanisic Michal
Affiliation:
- Department of Vascular and Endovascular Surgery, Angiology and Phlebology Poznan University of Medical Sciences, Ponzon,Poland
Keywords: Anticoagulants, chronic kidney disease, direct oral anticoagulants, vitamin K antagonists, pharmacologic properties, dialysis.
Abstract: In daily practice, chemical substances called “direct oral anticoagulants” or DOACs are more convenient to administer when set beside vitamin K antagonists (VKA) due to improved pharmacologic properties, fewer drug interactions and rapid onset of action. The objective of this review was to assess whether DOACs are the alternative for VKA in subjects with mild-to-moderate chronic kidney disease (CKD). An analysis of current DOAC trials and studies was performed focusing on subjects with CKD. This review concludes that although DOACS are not recommended in the course of advanced chronic kidney disease (CrCl<30mL/min) or during dialysis, DOACS are a reasonable choice for individuals with mild to moderate CKD.
Export Options
About this article
Cite this article as:
Zbigniew Krasiński *, Hubert Stępak , Andrzej Jawień and Michal Stanisic , Safety of New Oral Anticoagulants for Patients with Chronic Kidney Disease, Current Pharmaceutical Design 2018; 24 (38) . https://dx.doi.org/10.2174/1381612825666190130144051
DOI https://dx.doi.org/10.2174/1381612825666190130144051 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis
Cardiovascular & Hematological Disorders-Drug Targets The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part I: Epidemiology, Clinical Aspects and Diagnostic Options
Current Cardiology Reviews Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy
Cardiovascular & Hematological Disorders-Drug Targets Novel Antithrombotic Agents: Indirect Synthetic Inhibitors of Factor Xa and Direct Thrombin Inhibitors. Evidences from Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Renal Artery Stenosis: Current Perspectives on Imaging and Endovascular Management
Current Hypertension Reviews Effects of Maternal Obesity on Maternal and Fetal Health
Current Women`s Health Reviews Increased Serum HMGB-1, ICAM-1 and Metalloproteinase-9 Levels in Buerger’s Patients
Current Vascular Pharmacology Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry Fondaparinux: Pharmacology and Clinical Experience in Cardiovascular Medicine
Mini-Reviews in Medicinal Chemistry Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Current Pharmaceutical Design Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W. Wiedmann)]
Current Cancer Drug Targets New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery
Cardiovascular & Hematological Disorders-Drug Targets Approaches for the Cure of Type 1 Diabetes by Cellular and Gene Therapy
Current Gene Therapy Pharmacotherapy and HDL Cholesterol
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Use of Exogenous Enzymes in Human Therapy: Approved Drugs and Potential Applications
Current Medicinal Chemistry Discovery of Anticoagulant Drugs: A Historical Perspective
Current Drug Discovery Technologies Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews